CancerOption.com's President and CEO, Arnold Takemoto to Lecture at Cancer Conference in Japan.SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aug. 6, 1999-- (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CAOP) Conference is Sponsored by the American Cancer Control Society, Japan Branch, European Independent Analyst Group, Stockreporter.de Announces Investment Opinion on CancerOption.com CancerOption.com, Inc. (OTC BB:CAOP) announced today that President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Arnold Takemoto, has been invited to lecture at the 5th Annual Alternative Cancer Conference, sponsored by the American Cancer Control Society, Japan Branch in Chiba Makuhari Messe Makuhari Messe (幕張メッセ| , Japan. Doctors and speakers from around the world will be attending this distinguished forum on alternative and complementary approaches in the treatment of cancer. This conference will be held August 7 - 8, 1999. Corinne Wade, Co-Director of Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most for CancerOption.com, states, "Mr. Takemoto's presence at this conference not only brings exposure to CancerOption.com, but further extends our Company's mission of providing both traditional and alternative therapies, research and content that focus on cancer. Mr. Takemoto is a respected lecturer and has previously attended several international conferences this year including, Total Immunity for the Next Millenium last April and the International Conference on Advanced Medicine in Immune Disorders and Cancer in Germany." Ms. Wade further states, "Along with this notable invitation, CancerOption.com will be launching our portal in beta test A test of new or revised hardware or software that is performed by users at their facilities under normal operating conditions. Beta testing follows alpha testing. Vendors of packaged software often offer their customers the opportunity of beta testing new releases or versions, and the format at www.canceroption.com on August 12, 1999." CancerOption.com has received a strong buy recommendation from the Stockreporter.de, a leading European financial Internet publication at www.stockreporter.de. The Stockreporter.de specializes in the coverage of micro caps and undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. OTC and BB companies. Dennis C. Hass from Stockreporter.de comments, "CancerOption.com is one of the most exciting companies to come to our attention in recent years. Its growth potential in the cross-section of the two fastest growing industries, Internet and Pharma, is both very dynamic and unlimited. CancerOption.com's international expansion via the Internet therefore will assure its continues profitable growth into the next century." The successful team of Stockreporter.de is the first independent analyst to begin coverage of CancerOption.com and to release an investment opinion. Stockreporter.de has experienced outstanding success of its portfolio featuring FutureLink Distributions (OTC BB:FLNK FLNK Fully Associated Link ) and Teltran International (OTC BB:TLTG TLTG Too Lazy To Google ). CancerOption.com's mission is to provide a clear and concise informational stream of content in an effort to educate the general public and physicians on a variety of methods to enhance the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Within the CancerOption.com virtual community, forums discussing the latest research findings, clinical trials, traditional and alternative therapies as well as professional forums with oncologists, physicians and healthcare professionals will be available worldwide. CancerOption.com's protocols and targeted nutraceuticals work in conjunction with current traditional therapies and are recommended for anyone addressing immune deficiencies immune deficiency n. See immunodeficiency. . Educational materials, health links, supplements and content are available at www.canceroption.com. Disclaimer: This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion